Navigation Links
Icahn School of Medicine at Mount Sinai awarded $2.7 million from NIH to investigate novel therapy for eczema
Date:11/25/2013

The National Institutes of Health has awarded a research team at the Icahn School of Medicine at Mount Sinai $2.7 million to study systemic treatments for patients with moderate to severe atopic dermatitis (AD), also known as eczema. Currently, no treatments are available that achieve long-term remission without difficult side effects for this debilitating skin disorder, characterized by inflammation, severe itching, and a rash that can adversely affect many aspects of everyday life.

The team will investigate the efficacy of a new intravenous medication, ILV-094, which blocks IL-22, an important protein that has been shown in animal models to trigger epidermal growth and differentiation abnormalities and chronic inflammation, which are major features of AD. The researchers see the study as potentially groundbreaking in using "narrow pathway"-targeted immune interventions for not just AD, but other "allergic" inflammatory diseases of the skin or other organs, such as asthma.

At the Icahn School of Medicine at Mount Sinai, Emma Guttman, MD, PhD, Associate Professor of Dermatology, and Director of the Laboratory for Inflammatory Skin Diseases, and Mark Lebwohl, MD, Professor and Chair of Dermatology, will lead the study. James G. Krueger, MD, PhD, D. Martin Carter Professor and head of the Laboratory for Investigative Dermatology at The Rockefeller University, will oversee the mechanistic studies for the trial. Dr. Guttman has a joint appointment at Rockefeller and will conduct clinical and mechanistic studies at both institutions.

Dr. Guttman was the first investigator to show in humans that a separate population of T cells secrete interleukin 22 (IL-22) and she also discovered the importance of the Th22 pathway and IL-22 in AD.

"Dr. Guttman has been at the forefront of many of the most important strides in understanding the pathophysiology of atopic dermatitis," said Dr. Lebwohl. "This trial is an important step in developing safer treatments for patients with moderate to severe AD."

"I hope that this research results in a final proof of concept and a novel treatment for AD without side effects," said Dr. Guttman. The clinical trial is expected to last five years. The majority of the clinical trial, will be conducted at the Icahn School of Medicine at Mount Sinai.


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Icahn School of Medicine at Mount Sinai Honors Innovators in Scientific Research and Health Care Philanthropy at 2013 Commencement Ceremony
2. Icahn School of Medicine at Mount Sinai and Bene Pharmachem Gmbh to Collaborate on Clinical Studies for Mucopolysaccaridoses
3. Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration
4. Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles
5. World-Renowned Gastroenterologist Jean-Frédéric Colombel, MD, Joins the Icahn School of Medicine at Mount Sinai
6. Janina A. Longtine, MD of the Icahn School of Medicine at Mount Sinai Elected President of the Association for Molecular Pathology
7. A Best Manuscript Award Goes to the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai
8. A Best Manuscript Award goes to Icahn School of Medicine at Mount Sinai
9. Four Researchers from Icahn School of Medicine at Mount Sinai Among the 400 Most Highly Influential Biomedical Researchers in the World
10. Even Preschoolers View the Overweight Negatively
11. Catastrophic Head Injuries to High School Football Players Rising
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/15/2019)... , ... October 15, 2019 , ... ... FDA’s Most Recent IFU Guidance , **An FDAnews Webinar**, Tuesday, October 29, 2019, ... for Use (IFU) guidance have on new drug applications and biologics license applications? ...
(Date:10/11/2019)... ... ... Inland Detox, Inc. has just moved to a new location in the ... Temecula Valley and it’s the perfect place for long-term residential alcohol and substance ... well as double occupancy rooms, a 2nd home where all treatment takes place, a ...
(Date:10/10/2019)... , ... October 10, 2019 , ... ... Annual Conference, Nutrition 21 was excited to hear the significant results of an ... blood flow impact of Nitrosigine®. The clinical study poster entitled “The Acute Effects ...
(Date:10/8/2019)... ... , ... Dr. Amir HagShenas of Silicon Valley Smile Solutions uses effective treatments ... common and treatable condition. Dr. HagShenas’ goal is to treat gum disease ... including tender and bleeding gums, and to prevent gum disease from progressing. , Those ...
(Date:10/8/2019)... ... , ... Over the past three decades, Buffalo Wings & Rings has elevated ... by providing a higher-quality product and experience than the competition. Now, the club-level sports ... A MUG FOR THE CAUSE" campaign in support of Breast Cancer Awareness Month. ...
Breaking Medicine News(10 mins):
(Date:10/8/2019)... ... October 08, 2019 , ... Dr. Ryan McNally, ND, ... 2019 Academy of Integrative Health and Medicine conference. Their presentation titled Advances in Integrative ... and how they can be used to promote brain health, and reduce the debilitating ...
(Date:10/8/2019)... ... October 08, 2019 , ... Respected dentist, Dr. Kenneth ... to enhance his skill and knowledge of dental implant diagnosis, placement and maintenance. ... four-part series of classes that combines in-depth lectures with hands-on workshops. Halfway through ...
(Date:10/8/2019)... ... October 08, 2019 , ... Fresno resident Regina Tanner has been selected by ... donor honoree. Regina will walk alongside the float, Light in the Darkness, during the ... and attorney, became a living organ donor in the fall of 2016 when her ...
Breaking Medicine Technology: